This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
by Zacks Equity Research
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
by Zacks Equity Research
BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
by Zacks Equity Research
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
by Zacks Equity Research
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
by Zacks Equity Research
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
by Zacks Equity Research
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
by Zacks Equity Research
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
by Zacks Equity Research
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
Building a Position With 4 Top Relative Price Strength Stocks
by Nilanjan Choudhury
ENS, PCRX, CLS and ENVA are four stocks with explosive relative price strength.
New Strong Buy Stocks for February 11th
by Zacks Equity Research
FULT, FBNC, DAN, PCRX and OMVKY have been added to the Zacks Rank #1 (Strong Buy) List on February 11, 2025.
Best Value Stocks to Buy for February 11th
by Zacks Equity Research
OMVKY, PCRX and EZPW made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 11, 2025.
Should You Buy Pacira (PCRX) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Why Pacira (PCRX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
by Zacks Equity Research
Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.
Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
by Zacks Equity Research
Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.